Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
DaProphet,
Our CEO will take care of all the details in a series of RNSs.
Don’t try to teach a master what to do, and don’t compare with our competitors.
As stated in our last RNS dated 26-Mar-2021, wait till end of April 2021.
Until then, please keep calm and steady.
Be positive, and longer the wait, better the Clinical Validation and obtaining CE and other trademarks. The necessary JV/ Manufacturers/ Sales and Logistics agreements will be forthcoming soon.
bbrq648
Ugh, AVCT always pops up on this board..
So.. AVCT?
Government proposals
The problem the government is aiming to solve
Consumers need to know that COVID-19 tests they buy are of satisfactory quality. This requires tests with sensitivity that is high enough to apply in ‘real world’ settings that provide accurate results and avoid spreading the virus.
Excluding self-test kits, there is currently no legal requirement available for independent validation of COVID-19 tests performance. Entry to the market is controlled by CE marking which is currently a self-declaration process for the performance of this type of test kit or equipment. This means performance is not independently verified ahead of sale.
https://www.gov.uk/government/consultations/private-coronavirus-covid-19-testing-validation/private-covid-19-testing-validation
Ummm, why have AVCT gone for professional use rather than self test?
No independent validation of its performance? Cough cough.. Surely if it is that good they would aim for an independent validation for self testing and increase their market potential in the Uk both now and the future?
Robust real world testing is coming because too many (75%) of current tests do not do what they claim to do. Funny that!
I ment collaborations not contracts..
Look at these.. BRH need to deliver something soon.. Time waits for no man..
Global distribution agreement with ABCAM plc to sell Avacta'sSARS-CoV-2 research ELISA1 Affimer® reagents
Avacta's next generation cell and gene therapy joint venture with Daewoong Pharmaceutical secures Series A venture funding
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, announces that it has entered into a collaboration agreement with Bruker Corporation (Billerica, MA) (NASDAQ: BRKR, "Bruker") to evaluate the Affimer-based, bead assisted mass spectrometry ("BAMSTM") SARS-CoV-2 assay, that the Group has developed with Adeptrix Inc. (Beverley, MA) ("Adeptrix").
DaProphet,
Don’t be so smart, a wait with patience for several detailed BRH Live RNS to be posted here.
Are you going nuts? Who is going to publish Contracts, which are confidential agreement between two parties or more.
bbrq648
Casper we can spot genuine holders and traders way before they turn up.
DaP ...good point re-contracts.....show me AVCT contracts....EXACTLY!!!!...thanks
Casper786...
The innova test was labeled the same. (for professional use).mcap makes no sense to me in this argument.
Avacta will probably be looking at an entry into Nasdaq by christmas imo. So single digit billions is small fry there..
Apples & oranges comparing brh test to a lft.
Brh tests are not going to be for home use,
We've already had that discussion plenty of times before...
The share price In the long term its all about establishing marketing and partnerships deals..
Something brh still hasn't sorted out as yet until a further update...
No point speculating. We need written facts/contracts... There the real things that sends the share price to a different level.
Come on TB.. Pull your finger out instead of investing elsewhere...
Make our device as common as a lottery machine and the country need never lockdown again . Enter schools, pubs, clubs, footy matches etc etc knowing your safe.
just very very quickly...
avct rns clearly states....it for professional use.......this kit you will not be able to use at home...
with our test...its not based on skills.....so yes one would be able to use it at home....thats if they can afford the DEVICE...ok fair point if you say....who is going to buy expensive device.....well ....imagine.....our device being at every post office....school...bus station......u go in give a sample.....walk away......
one device can have a livepool fan sample.......manu fan sample.....mancity fan sample..........after little time....each individual can get a bleep....on their phone...."because testing can be linked via QR coding to a phone app, and device locations don’t HAVE to be all in the one locale"......hence.....no queue required....
also....
WE could if we want...go for LFT single device.....we was told we was working on this....but never heard anything from them after initial rns in dec......i wouldnt be surprised....come winter.....our PARAYTEC has two tests on the go.....SINGLE and MULTIPLEX.....
Avct has their market YES...we have ours......
what most fail to undertstand......we aimed for the market we have right from the start..in April 2020....we aimed to open the ECONOMY again......so far we are proving right....and our APPROACH has been the BEST......some of these LFT tests...were suppose to be out last summer....here we are no-where to be seen.....
Anyways from my end.....i feel BRH at £25m is much much undervalued.....compared to its peers...like say avct whos m/c is approx £650m..........comes christmas.....if both were to x 10...........brh m/c would be £250MILLION.......avct £6.5BILLION....one needs to ask themselves which is relistic.....
and yes we are also going GLOBAL.....
HAPPY DAYS!!!!
low viral loads.
Not accurate/comprehensive enough.
Our test machines could be in all schools, offices, walk-in government test centres, events, stadiums, large wedding venues, hotels, cruise ships, police stations, conference centres, health gyms, swimming pools etc., etc., etc......
Massive potential........